Best Biopharma Outsourcing Companies in Washington, United States
The 30 best Biopharma Outsourcing companies in Washington, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Just Biotherapeutics.
Our analysis of 50 Biopharma Outsourcing companies
$6.3b in tracked funding; 77% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Biopharma Outsourcing companies in Washington
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AGC Biologics CDMO focused on development of mammalian and microbial-based therapeutic proteins | — | — | Unfunded | 1,290 | Patricio Massera CEO | HubSpot CMS HubApple iCloud MailSalesforce+20 | 20 patents Recombinant protein expression vectors and continuous high‑density cell culture bioprocessing | — |
| 2 | Ascensus Specialties Producer of specialty chemicals | — | — | Acquired | 248 248 → 161 (-35%) | — | Craft CMSPHPSalesforce+12 | — | — |
| 3 | axio research Axio Research is a pharmaceuticals company specializing in data monitoring services. | — | — | Acquired | 30 | — | — | — | — |
| 4 | cognition studio, inc Helping life science leaders build trust, draw mission-aligned investors, and focus on human impact. | — | — | — | 45 | — | — | — | — |
| 5 | global bioclinical Global BioClinical specializes in clinical research, project and quality management, trial planning along… | — | — | Private | 7 | — | — | — | — |
| 6 | Jubilant HollisterStier CDMO offering sterile and non-sterile manufacturing services | — | — | Unfunded | 1,389 | — | WordPressMySQLPHP+28 | 4 patents Manufacturing concentrated allergen extracts for diagnostic and therapeutic pharmaceutical use | — |
| 7 | Just-Evotec Biologics Provider of diversified CDMO services | — | — | Unfunded | 95 | — | — | 96 patents Automated biomanufacturing and purification systems for protein therapeutics, including filtration and AI design | — |
| 8 | Loginov Tech Provider of software solutions and custom development for multiple industries | — | — | Unfunded | — | Ilya Loginov Founder & CEO | — | — | — |
Top 12 Biopharma Outsourcing companies in Washington
#1
Series B · Seattle, Washington · founded 2020 · 14 employees$70Mraised▾
Developer of engineered cell-based therapeutics to restore vision. The company is advancing cell-based therapies and in vivo reprogramming to restore vision loss caused by the deterioration of functional tissue for people with degenerative ocular diseases.
- Jan 2026Conventional Debt$150M
- Jan 2026Series B$85M
- Jul 2023Series A$70M
- 2021Seed—
#2
Series A · Seattle, Washington · founded 2022 · 34 employees$85Mraised▾
InduPro is a biotechnology company that focuses on bringing proteins on the cell surface closer together, manipulating their interactions to open up new possibilities for treating various conditions. They have a multidisciplinary team with backgrounds in pharma, academia, and biotech, and they are dedicated to impacting patients' lives through innovative drug development.
- Dec 2025Series A—
- Jun 2024Series A$85M
#3
Series A · Seattle, Washington · founded 2016 · 14 employees$72.8Mraised▾
Limited information available
- Dec 2024Series A$22.5M
- Feb 2022Series A$50M
- May 2019Grant (prize money)$300K
#4
Series B · Spokane, Washington · founded 2017 · 79 employees$46.2Mraised▾
Contract manufacturer of pharmaceuticals
- Sep 2023Series B$25M
- Sep 2020Series B$12.2M
- Feb 2020Series A$9.1M
#5
Acquired · Seattle, Washington · founded 2014 · 79 employees$123.5Mraised▾
Designing technologies to accelerate biotherapeutic development and to reduce manufacturing costs. It designs novel technologies to accelerate biotherapeutic development. It will integrate protein design, process design, and manufacturing plant design to increase translation speed to the clinic and to reduce manufacturing costs. Its services include molecular design, process design, drug product design, and plant design.
- Jun 2018Series B$35M
- Aug 2017Series B$59.5M
- Jul 2016Series A$14M
- Sep 2015Series A$15M
#6
Acquired · Seattle, Washington · founded 2008 · 160 employees$67.5Mraised▾
Provider of trans-formative therapy development and commercialisation services
- Dec 2018Series D$67.5M
- Nov 2012Grant (prize money)$675.1K
- Feb 2012Grant (prize money)$149.5K
- Feb 2012Grant (prize money)$149.5K
#7
Series A · Issaquah, Washington · founded 2018 · 8 employees$23.4Mraised▾
Manufacturer of psychedelic drug discovery & research services. They also offers psychedelic formulations, drug safety, efficacy screening, intellectual property to fund progress, and technological innovation services.
- Sep 2021Series A$22M
- 2020Seed$1.4M
#8
Seed · Seattle, Washington · founded 2022 · 3 employees$720Kraised▾
Developer of AI-driven platform for high-throughput drug screening in live animals. The platform combines robotics, computer vision, and deep learning to automate drug screening. It analyzes movement, behavior, and lifespan in models to quantify therapeutic impact. The system uncovers biological effects and discovers therapeutic candidates.
- Sep 2024Grant (prize money)$324.2K
- Jan 2024Seed$720K
#9
Funding Raised · Seattle, Washington · founded 2005 · 14 employees$22.6Mraised▾
Etubics Corporation is developing vaccines utilizing a patented advanced generation adenovirus delivery platform and a validated manufacturing human cell line, collectively the Etubics Platform. The company developing therapeutic vaccines for colorectal, breast, and HPV-induced cancers; preventive vaccines for the treatment of influenza and Ebola. The Company has completed Phase I/IIa clinical trials with its lead product, ETBX-011 (a viral vector against CEA antigen) to treat colorectal cancer.
- Sep 2014Grant (prize money)$202.7K
- May 2014Grant (prize money)$4.4M
- Apr 2014Grant (prize money)$4.5M
- Jul 2011Grant (prize money)$1.3M
#10
Series A · Seattle, Washington · founded 2017 · 10 employees$6Mraised▾
Provider of verification services for pharmaceutical products
- Feb 2018Series A$5M
- Oct 2017Seed$1M
#11
Series A · Seattle, Washington · founded 2004 · 15 employees$3Mraised▾
Accium BioSciences offers Accelerated Mass Spectrometry (AMS) services such as mass balance ADME, absolute bioavailability, metabolite profiling and microtracing studies (preclinical and clinical) services.The company's key offering includes 14C/12C ratio measurement of clinical samples that support drug development studies.Their AMS facility features a National Electrostatics Corporation 1.5 SDH-1 Pelletron Accelerator Mass Spectrometer that operates with two ion sources of 40-sample and 134-sample capacities and claims to have 0.3% precision and accuracy for all sample measurements. They also offer HPLC chromatography, sample preparation, and method development services. Accium processes clinical samples such as plasma, whole blood, urine, HPLC fractions, processed and unprocessed feces, homogenized tissue, and many other sample types. The company claims that its services are used by five of the top ten global pharmaceutical companies including Merck, Novartis and Bristol-Myers Squibb.
- Jan 2006Series A$3M
#12
Late Stage · Seattle, Washington · founded 2002 · 96 employees—raised▾
CRO focused on providing patient recruitment services
- Sep 2021PE—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising